JP2018528229A5 - - Google Patents

Download PDF

Info

Publication number
JP2018528229A5
JP2018528229A5 JP2018515059A JP2018515059A JP2018528229A5 JP 2018528229 A5 JP2018528229 A5 JP 2018528229A5 JP 2018515059 A JP2018515059 A JP 2018515059A JP 2018515059 A JP2018515059 A JP 2018515059A JP 2018528229 A5 JP2018528229 A5 JP 2018528229A5
Authority
JP
Japan
Prior art keywords
alkyl
compound
salt
heterocyclyl
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018515059A
Other languages
English (en)
Japanese (ja)
Other versions
JP6795588B2 (ja
JP2018528229A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/072216 external-priority patent/WO2017050714A1/en
Publication of JP2018528229A publication Critical patent/JP2018528229A/ja
Publication of JP2018528229A5 publication Critical patent/JP2018528229A5/ja
Application granted granted Critical
Publication of JP6795588B2 publication Critical patent/JP6795588B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018515059A 2015-09-22 2016-09-20 ブロモドメイン阻害薬としての使用のためのピリジノンジカルボキサミド Expired - Fee Related JP6795588B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562221649P 2015-09-22 2015-09-22
US62/221,649 2015-09-22
PCT/EP2016/072216 WO2017050714A1 (en) 2015-09-22 2016-09-20 Pyridinone dicarboxamide for use as bromodomain inhibitors

Publications (3)

Publication Number Publication Date
JP2018528229A JP2018528229A (ja) 2018-09-27
JP2018528229A5 true JP2018528229A5 (https=) 2019-10-17
JP6795588B2 JP6795588B2 (ja) 2020-12-02

Family

ID=56943545

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018515059A Expired - Fee Related JP6795588B2 (ja) 2015-09-22 2016-09-20 ブロモドメイン阻害薬としての使用のためのピリジノンジカルボキサミド

Country Status (9)

Country Link
US (1) US10370356B2 (https=)
EP (1) EP3353162A1 (https=)
JP (1) JP6795588B2 (https=)
KR (1) KR20180052762A (https=)
CN (1) CN108137541B (https=)
AU (1) AU2016326864A1 (https=)
CA (1) CA2998545A1 (https=)
RU (1) RU2018112312A (https=)
WO (1) WO2017050714A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6885968B2 (ja) 2016-05-24 2021-06-16 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited ブロモドメイン阻害薬としてのピリジンジカルボキサミド誘導体
CN111163780A (zh) 2017-07-18 2020-05-15 诺维逊生物股份有限公司 作为腺苷拮抗剂的杂环化合物
CA3070073A1 (en) 2017-07-18 2019-01-24 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
GB201716369D0 (en) * 2017-10-06 2017-11-22 Glaxosmithkline Intellectual Property (No 2) Ltd Compounds
GB201716392D0 (en) * 2017-10-06 2017-11-22 Glaxosmithkline Intellectual Property (No 2) Ltd Compounds
EP4389277A3 (en) * 2017-10-18 2024-10-09 Biotage AB Sample clean up device and method of using it
GB201814167D0 (en) 2018-08-31 2018-10-17 Glaxosmithkline Ip No 2 Ltd Compounds
US11192900B2 (en) 2018-10-30 2021-12-07 Nuvation Bio Inc. Substituted 1,6-dihydropyridinones and 1,2-dihydroisoquinolinones as bet inhibitors
AU2020208644A1 (en) 2019-01-18 2021-08-26 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
WO2020150676A1 (en) 2019-01-18 2020-07-23 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
KR102677015B1 (ko) 2019-07-02 2024-06-19 누베이션 바이오 인크. Bet 억제제로서의 헤테로시클릭 화합물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
KR100828982B1 (ko) 2000-12-28 2008-05-14 시오노기세이야쿠가부시키가이샤 칸나비노이드 2형 수용체 친화 작용을 갖는 피리돈 유도체
ATE447971T1 (de) * 2002-02-19 2009-11-15 Shionogi & Co Antipruriginosa
GB0211759D0 (en) 2002-05-22 2002-07-03 Glaxo Group Ltd Novel compounds
US7629347B2 (en) 2002-10-09 2009-12-08 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
EP1433788A1 (en) 2002-12-23 2004-06-30 Aventis Pharma Deutschland GmbH Pyrazole-derivatives as factor Xa inhibitors
CN1901958B (zh) 2003-11-03 2011-03-09 葛兰素集团有限公司 流体分配装置
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
BR112015009850A2 (pt) 2012-11-08 2017-07-11 Bristol Myers Squibb Co compostos de piridila substituídos por heteroarila úteis como moduladores de quinase
JP2016507496A (ja) * 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションZenith Epigenetics Corp. ブロモドメイン阻害剤としての新規複素環式化合物
HUE043568T2 (hu) 2013-03-14 2019-08-28 Glaxosmithkline Ip No 2 Ltd 2,3-diszubsztituált 1-acil-4-amino-1,2,3,4-tetrahidrokinolin származékok és bromodomén inhibitorokkénti felhasználásuk
WO2015011252A1 (en) 2013-07-26 2015-01-29 F. Hoffmann-La Roche Ag Pyrimidine-pyridinone serine/threonine kinase inhibitors
JP6542212B2 (ja) 2013-07-31 2019-07-10 ゼニス・エピジェネティクス・リミテッドZenith Epigenetics Ltd. ブロモドメイン阻害剤としての新規キナゾリノン
JP6532599B2 (ja) 2015-09-02 2019-06-19 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited ブロモドメイン阻害薬としての使用のためのピリジノンジカルボキサミド
KR20180059551A (ko) 2015-10-05 2018-06-04 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 브로모도메인 억제제로서 2-옥소-1,2-디하이드로피리딘-3,5-디카복스아미드 화합물
US10934272B2 (en) 2016-04-07 2021-03-02 Glaxosmithkline Intellectual Property (No. 2) Limited Pyridyl derivatives as bromodomain inhibitors
JP6885968B2 (ja) 2016-05-24 2021-06-16 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited ブロモドメイン阻害薬としてのピリジンジカルボキサミド誘導体

Similar Documents

Publication Publication Date Title
JP2018528229A5 (https=)
RU2018112312A (ru) Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена
JP2018529737A5 (https=)
JP2013510124A5 (https=)
JP2014511891A5 (https=)
RU2018142988A (ru) Производные пиридиндикарбоксамида в качестве ингибиторов бромодомена
JP2014511892A5 (https=)
PH12020551616A1 (en) N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof
JP2014129360A5 (https=)
JP2019502763A5 (https=)
JP2014507455A5 (https=)
JP2013527243A5 (https=)
RU2016137181A (ru) Противофиброзные пиридиноны
JP2014511893A5 (https=)
RU2013121788A (ru) Ингибиторы репликации вич
JP2013519675A5 (https=)
JP2013510123A5 (https=)
JP2020529994A5 (https=)
JP2015516427A5 (https=)
JP2013209405A5 (https=)
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
JP2019516761A5 (https=)
JP2017517565A5 (https=)
JP2020511536A5 (https=)
JP2015521195A5 (https=)